NCT02804230 is a NA clinical trial of Neuro Ablation - Functional in Epilepsy, sponsored by InSightec.

Who is sponsoring NCT02804230?

NCT02804230 is sponsored by InSightec.

What drugs are being tested in NCT02804230?

Interventions in NCT02804230: Neuro Ablation - Functional.

Is NCT02804230 still recruiting?

NCT02804230 is currently status unknown. Last updated 10 September 2022.

Last reviewed 2022-09-10 · How we verify

NCT02804230

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

MR-Guided Focused Ultrasound in the Treatment of Focal Epilepsy (EP001)

Status unknown NA Last updated 10 September 2022

What this trial tests

NA trial testing Neuro Ablation - Functional in Epilepsy in 20 participants. Status unknown.

Timeline

7 June 2016

Primary endpoint
23 June 2023

30 June 2023

Quick facts

Lead sponsor	InSightec
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	20
Start date	7 June 2016
Primary completion	23 June 2023
Estimated completion	30 June 2023
Sites	4 locations across United States

Drugs / interventions tested

Neuro Ablation - Functional

Conditions studied

Epilepsy — all drugs for Epilepsy →

Sponsor

InSightec — full company profile →

Who can join

Adults 18 to 80, any sex, with Epilepsy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to evaluate the feasibility, safety, and initial effectiveness of Exablate thermal ablation of a focal epileptic target area in the brain of patients suffering from medication-refractory epilepsy, using the Exablate transcranial system to produce multiple sonications targeted in the focus of interest. The investigators will establish the feasibility and collect data to establish the basic safety of this type of treatment as the basis for later studies that will evaluate its full clinical efficacy.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Clinical Intervention Using Focused Ultrasound (FUS) Stimulation of the Brain in Diverse Neurological Disorders.
Baek H, Lockwood D, Mason EJ, Obusez E, et al · · 2022 · cited 48× · PMID 35614924 · DOI 10.3389/fneur.2022.880814
Magnetic Resonance-Guided Focused Ultrasound : Current Status and Future Perspectives in Thermal Ablation and Blood-Brain Barrier Opening.
Lee EJ, Fomenko A, Lozano AM. · · 2019 · cited 45× · PMID 30630292 · DOI 10.3340/jkns.2018.0180
Current and emerging brain applications of MR-guided focused ultrasound.
Meng Y, Suppiah S, Mithani K, Solomon B, et al · · 2017 · cited 29× · PMID 29034095 · DOI 10.1186/s40349-017-0105-z
How technology is driving the landscape of epilepsy surgery.
Dorfer C, Rydenhag B, Baltuch G, Buch V, et al · · 2020 · cited 27× · PMID 32227349 · DOI 10.1111/epi.16489
Magnetic Resonance-Guided Focused Ultrasound in Neurosurgery: Taking Lessons from the Past to Inform the Future.
Jung NY, Chang JW. · · 2018 · cited 24× · PMID 30369860 · DOI 10.3346/jkms.2018.33.e279
Low Intensity Focused Ultrasound for Epilepsy- A New Approach to Neuromodulation.
Bubrick EJ, McDannold NJ, White PJ. · · 2022 · cited 22× · PMID 36474831 · DOI 10.1177/15357597221086111
MRI Guided Focused Ultrasound-Mediated Delivery of Therapeutic Cells to the Brain: A Review of the State-of-the-Art Methodology and Future Applications.
Ahmed N, Gandhi D, Melhem ER, Frenkel V. · · 2021 · cited 18× · PMID 34220679 · DOI 10.3389/fneur.2021.669449
Targeted manipulation of pain neural networks: The potential of focused ultrasound for treatment of chronic pain.
Todd N, McDannold N, Borsook D. · · 2020 · cited 13× · PMID 32534900 · DOI 10.1016/j.neubiorev.2020.06.007

Verify or expand the search:

Other recruiting trials for Epilepsy

Currently open trials in the same condition.

NCT07095933 — The Safety and Efficacy Evaluation of Everolimus as an Adjunctive Treatment for Focal Refractory Epilepsy · EARLY_PHASE1 · recruiting
NCT07224191 — Hippocampal Oscillations During Exploration · NA · recruiting
NCT07219407 — A Long-term Study of the Safety and Effectiveness of RAP-219 in Adults With Focal Onset Seizures · Phase 2 · recruiting
NCT07417280 — LIFUS For Neurological Disorders · NA · recruiting
NCT07490769 — Levetiracetam Three Times Daily in Epilepsy · Phase 3 · recruiting

Other InSightec trials

Trials by the same sponsor.

NCT04667715 — Safety and Effectiveness of Blood-Brain Barrier Disruption (BBBD) in Subjects With Suspected Infiltrating Glioma · NA · withdrawn
NCT05539196 — A Post-Approval Registry for Exablate 4000 Type 1.0 and Type 1.1 for Unilateral Pallidotomy for the Treatment of Advance · recruiting
NCT05089786 — Echo-Focusing in Patients With Treatment-Resistant Neurologic and Psychiatric Indications (EF001) · NA · unknown
NCT05565443 — MR-guided Focused Ultrasound Plus GCase · NA · recruiting
NCT05317858 — Blood-brain Barrier (BBB) Opening Using Exablate Focused Ultrasound With Standard of Care Treatment of NSCLC Brain Mets · Phase 3 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02804230 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by InSightec
Last refreshed: 10 September 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02804230.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing